Illumina to buy proteomics company Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 23 June, 2025

sponsored by Oncology Drugs to Watch: Top takeaways from ASCO 2025 Clarivate oncology experts deliver clear, strategic insights on 13 major drugs from ASCO 2025. Learn what the latest data means for the future of cancer treatment and drug development. Download the report

presented by Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

news Compass claims Phase 3 win in depression for psilocybin drug, moves closer to FDA filing Updated: A puzzling update from Novo Nordisk and new data from Roche at #ADA25 Vertex's diabetes cell therapy allows 10 patients to come off insulin Illumina to buy SomaLogic for $350M, pushing further into proteomics

Jun 24 10:30am ET Expanding access, accelerating trials: The power of community-based oncology research sponsored by START Research Jun 26 11:00am ET May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI based CLD Platform sponsored by Rentschler Biopharma Jul 10 11:00am ET Beyond the data deluge: Immune profiling in early immuno-oncology trials sponsored by Precision for Medicine Jul 22 2:00pm ET New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform sponsored by Natera Jul 24 12:00pm ET Predict tumor response and identify more patients for therapy with epigenomic biomarkers sponsored by Guardant

Supply chain strategy just got more complicated — is your manufacturing model still viable? Trade tensions, policy shifts, and geopolitical uncertainty have biopharma executives rethinking manufacturing and distribution. How are the experts doing it now? Find out — get your spot today.

endpoints pharma Inside the FDA’s ‘listening’ tour: Officials agree US lags behind China on drug development CHMP recommends five new drugs, reconsiders Eli Lilly’s Kisunla  UK's NICE says Lilly, Eisai's Alzheimer's drugs aren't worth national coverage

in case you missed it 1. Pharma companies are weighing how a drug’s IP location could impact tariffs 2. Early-stage investor Syncona readjusts priorities due to bleak biotech market 3. Peer Review Roche's venture arm chief to step down in 2026; AstraZeneca obesity leader has retired 4. FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes 5.